For anticancer therapy, platelets were also engineered to express surface-bound necrosis-factor-related apoptosis-inducing ligand (TRAIL), a cytokine that induces apoptosis selectively in a wide range of cancer cells while sparing normal ones [207] (Figure 1). Here, TNFSF10 is linked to cancer.